应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PDSB PDS Biotechnology Corporation
交易中 08-14 10:07:13 EDT
0.2352
+0.0020
+0.86%
最高
0.2444
最低
0.2261
成交量
41.90万
今开
0.2300
昨收
0.2332
日振幅
7.85%
总市值
1,313万
流通市值
1,280万
总股本
5,582万
成交额
9.84万
换手率
0.77%
流通股本
5,440万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
PDS生物技术公司宣布战略重组:聚焦PDS0301进军转移性结直肠癌,并为PDS0101制定合作策略
美股速递 · 08-11
PDS生物技术公司宣布战略重组:聚焦PDS0301进军转移性结直肠癌,并为PDS0101制定合作策略
PDS Biotechnology宣布终止对PDS0101三期Versatile-003试验的内部投资
美股速递 · 08-11
PDS Biotechnology宣布终止对PDS0101三期Versatile-003试验的内部投资
PDS Biotechnology Corporation公布NCI主导的转移性结直肠癌二期临床试验第一阶段积极中期数据
美股速递 · 04-15
PDS Biotechnology Corporation公布NCI主导的转移性结直肠癌二期临床试验第一阶段积极中期数据
PDS Biotechnology Corporation宣布调整三期Versatile-003试验方案 将无进展生存期纳入中期分析主要终点以支持加速审批
美股速递 · 02-20
PDS Biotechnology Corporation宣布调整三期Versatile-003试验方案 将无进展生存期纳入中期分析主要终点以支持加速审批
暂无数据
公司概况
公司名称:
PDS Biotechnology Corporation
所属市场:
NASDAQ
上市日期:
--
主营业务:
PDS Biotechnology Corporation于2009年1月22日根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司,专注于发现,开发和寻求商业化的新颖的以医院为基础的治疗方案,能够改变治疗模式和危及生命的管理。
发行价格:
--
{"stockData":{"symbol":"PDSB","market":"US","secType":"STK","nameCN":"PDS Biotechnology Corporation","latestPrice":0.2352,"timestamp":1786716409132,"preClose":0.2332,"halted":0,"volume":419018,"delay":0,"changeRate":0.00857632933104632,"floatShares":54404300,"shares":55815700,"eps":-0.665407,"marketStatus":"交易中","change":0.002,"latestTime":"08-14 10:07:13 EDT","open":0.23,"high":0.2444,"low":0.2261,"amount":98390.1822543,"amplitude":0.078473,"askPrice":0.2355,"askSize":2260,"bidPrice":0.233,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.665407,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786737600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1443672000000,"exchange":"NASDAQ","adjPreClose":0.2332,"preHourTrading":{"tag":"盘前","latestPrice":0.231,"preClose":0.2332,"latestTime":"09:14 EDT","volume":90507,"amount":20843.21091237,"timestamp":1786713273770,"change":-0.0022,"changeRate":-0.009434,"amplitude":0.063894},"postHourTrading":{"tag":"盘后","latestPrice":0.2379,"preClose":0.2332,"latestTime":"19:56 EDT","volume":121455,"amount":28415.17084,"timestamp":1786665371908,"change":0.0047,"changeRate":0.020154,"amplitude":0.074185},"volumeRatio":0.534911,"impliedVol":1.0437,"impliedVolPercentile":0.8406},"requestUrl":"/m/hq/s/PDSB/tweets","defaultTab":"tweets","newsList":[{"id":"1133631174","title":"PDS生物技术公司宣布战略重组:聚焦PDS0301进军转移性结直肠癌,并为PDS0101制定合作策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1133631174","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133631174?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:26","pubTimestamp":1786451201,"startTime":"0","endTime":"0","summary":"PDS生物技术公司(PDS Biotechnology Corporation)近日正式对外宣布一项重大战略调整。此次重组表明,公司将把研发重心全力倾斜至其核心候选药物PDS0301之上,目标直指转移性结直肠癌(mCRC)这一严峻的适应症领域。与此同时,针对另一款关键在研产品PDS0101,管理层也已明确规划出一条全新的合作路径,冀望通过外部联盟来加速其临床开发与商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116772975","title":"PDS Biotechnology宣布终止对PDS0101三期Versatile-003试验的内部投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1116772975","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116772975?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:26","pubTimestamp":1786451169,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation(代码:PDSB)披露,已决定停止对PDS0101三期Versatile-003临床试验的内部资金投入。这一战略调整意味着,这家生物科技公司不再继续为该项关键试验提供内部资本支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116114948","title":"PDS Biotechnology Corporation公布NCI主导的转移性结直肠癌二期临床试验第一阶段积极中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1116114948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116114948?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:46","pubTimestamp":1776257183,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation宣布,其PDS01ADC在由国家癌症研究所(NCI)主导的转移性结直肠癌(MCRC)二期临床试验第一阶段的中期研究数据已正式发表。此次公布的数据显示积极的临床效果,为后续治疗方案的推进提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169029304","title":"PDS Biotechnology Corporation宣布调整三期Versatile-003试验方案 将无进展生存期纳入中期分析主要终点以支持加速审批","url":"https://stock-news.laohu8.com/highlight/detail?id=1169029304","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169029304?lang=zh_cn&edition=full","pubTime":"2026-02-20 21:31","pubTimestamp":1771594294,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation(简称PDS Biotech)近日公布,其已对三期临床试验Versatile-003的研究方案作出重要修订。新版方案将无进展生存期(PFS)设定为中期分析的主要终点指标,这一调整旨在为后续可能的加速审批提供关键数据支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pdsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.6879},{"period":"1month","weight":-0.6899},{"period":"3month","weight":-0.826},{"period":"6month","weight":-0.6672},{"period":"1year","weight":-0.799},{"period":"ytd","weight":-0.6971}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PDS Biotechnology Corporation于2009年1月22日根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司,专注于发现,开发和寻求商业化的新颖的以医院为基础的治疗方案,能够改变治疗模式和危及生命的管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.025289},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.061437},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.164348},{"month":4,"riseRate":0.454545,"avgChangeRate":0.079515},{"month":5,"riseRate":0.545455,"avgChangeRate":0.158069},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.000335},{"month":7,"riseRate":0.545455,"avgChangeRate":0.070482},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.070384},{"month":9,"riseRate":0.3,"avgChangeRate":-0.078335},{"month":10,"riseRate":0.3,"avgChangeRate":-0.019658},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.002317},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.051726}],"exchange":"NASDAQ","name":"PDS Biotechnology Corporation","nameEN":"PDS Biotechnology Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PDS Biotechnology Corporation(PDSB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PDS Biotechnology Corporation(PDSB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PDS Biotechnology Corporation,PDSB,PDS Biotechnology Corporation股票,PDS Biotechnology Corporation股票老虎,PDS Biotechnology Corporation股票老虎国际,PDS Biotechnology Corporation行情,PDS Biotechnology Corporation股票行情,PDS Biotechnology Corporation股价,PDS Biotechnology Corporation股市,PDS Biotechnology Corporation股票价格,PDS Biotechnology Corporation股票交易,PDS Biotechnology Corporation股票购买,PDS Biotechnology Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PDS Biotechnology Corporation(PDSB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PDS Biotechnology Corporation(PDSB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}